Shares of Celcuity Inc. (CELC) soared in the post-market trading session; this is what happened recently

Shares of Celcuity Inc. (CELC) were up 4.87% to trade at $ 29.3 in the secondary market at the time of writing. CELC stock closed Monday’s session at $ 27.94, a gain of 29.35%. CELC share volume traded around 4.86 million shares, which is higher than the average daily volume of 0.46 million shares over the past 50 days.

What is the recent news of Cecluity’s operational activities?

The 12e In April, Celcuity attended the American Association for Cancer Research (AACR) annual meeting and presented the results of its studies that evaluated gedatolisib, inavolisib and navitoclax in breast tumors. and ovary. Gedatolisib is a pan-P13K / mTOR inhibitor, inavolisib is a P13K-α inhibitor and navitoclax is a BCL inhibitor. Two e-posters were used by the company for the presentation of these studies and results.

Study results and characteristics

The posters presented the use of the CELsignia test to characterize the role of the nodes of the RAS network; The CELsignia RAS network activity assay used by the company identifies the overactive RAS network signal generated by tumors in patients with ovarian or breast cancer. In addition, CELsignia also characterizes gedatolisib, inavolisib, navitoclax as well as the RAS signaling role in the phospholipid-initiated signaling activity that occurs through the lysophosphatidic acid receptor family ( APL) of GPCRs in tumor cells and cell lines of patients with ovarian and breast cancer. .

The results of these studies indicated that there is a potential benefit not only in inhibiting P13k-α signaling, but also in inhibiting all class 1 P13K isoforms as well as mTOR for the treatment of P13K signaling tumors.

License agreement with pharmaceutical giant Pfizer

CELC stock jumped more than 50% on the 9e April after announcing a licensing agreement with world-renowned pharmaceutical company Pfizer PFE. In the agreement, Celcuity made $ 10 million to Pfizer as an upfront payment under the terms and Pfizer will receive up to $ 330 million in development and sales from Celcuity as well as royalties on future sales.

In addition, Celcuity also announced the promise to present preliminary data from the recent ongoing Phase 1b study evaluating gedatolisib in combination with Pfizer’s Ibrance as well as endocrine therapy in Er + / HER2 – cancer patients. advanced or metastatic breast. The phase II / III study of gedatolisib with the pfixer combo is expected to start in mid-2022.

Overview of Celcuity’s General History

Celcuity is a clinical-stage biotechnology company that specifically creates new therapies and treatments in a unique and innovative approach to cancer treatments. The company is distinguished by its focus on creating integrated companion diagnostics and a therapeutic strategy for cancer patients. The goal of this guidance is to improve and prolong the life of cancer patients.

Companion diagnostics is able to identify the driver of cancer in the patient, and then therapeutic efforts target the driver of cancer at the molecular level. CELC’s proprietary stock diagnostic platform is known as CELsignia, which has the technical ability to analyze living tumor cells and then identify new groups of cancer patients for whom targeted therapies are favorable. This diagnosis is reinforced by CELsigniaCDx which supports the advancement of new indications in development for established targeted therapies.

Based on this therapeutic strategy and an integrated companion diagnostics, Celcuity is positioning itself in the cancer treatment and therapy market in a unique way to treat the cancer driver in the most suitable way for patients.

Comments are closed.